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We briefly review the characteristics of pituitary tumors associated with multiple endocrine neoplasia type 1.
Multiple endocrine neoplasia type 1 is an autosomal-dominant disorder most commonly characterized by tumors
of the pituitary, parathyroid, endocrine-gastrointestinal tract, and pancreas. A MEDLINE search for all available
publications regarding multiple endocrine neoplasia type 1 and pituitary adenomas was undertaken. The
prevalence of pituitary tumors in multiple endocrine neoplasia type 1 may vary from 10% to 60% depending on
the studied series, and such tumors may occur as the first clinical manifestation of multiple endocrine neoplasia
type 1 in 25% of sporadic and 10% of familial cases. Patients were younger and the time between initial and
subsequent multiple endocrine neoplasia type 1 endocrine lesions was significantly longer when pituitary
disease was the initial manifestation of multiple endocrine neoplasia type 1. Tumors were larger and more
invasive and clinical manifestations related to the size of the pituitary adenoma were significantly more
frequent in patients with multiple endocrine neoplasia type 1 than in subjects with non-multiple endocrine
neoplasia type 1. Normalization of pituitary hypersecretion was much less frequent in patients with multiple
endocrine neoplasia type 1 than in subjects with non-multiple endocrine neoplasia type 1. Pituitary tumors in
patients with multiple endocrine neoplasia type 1 syndrome tend to be larger, invasive and more symptomatic,
and they tend to occur in younger patients when they are the initial presentation of multiple endocrine
neoplasia type 1.
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INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1, OMIM
#131100) is an autosomal-dominant disorder mostly char-
acterized by tumors of the pituitary, parathyroid, endocrine-
gastrointestinal tract, and pancreas (1). Adrenocortical and
thyroid tumors, cutaneous lipomas, meningiomas, facial
angiofibromas and gastric, thymic or bronchial carcinoid
can also occur (2–5). The phenotype of MEN1 may vary
widely, and this neoplasia should be suspected in patients
with an endocrinopathy of two of the three main affected
glands or with one endocrinopathy of one of these organs
plus a first-degree relative who is affected by MEN1
syndrome (6).
At the beginning of the past century, autopsy findings of a
patient with acromegaly and four enlarged parathyroid
glands were reported (7). In 1953, Underdahl et al.
published the first review of MEN1 syndrome in which
they described 14 cases in the literature and eight cases from
the Mayo Clinic (8). In 1954, Wermer et al. suggested that
this syndrome followed an autosomal-dominant inheri-
tance pattern with high penetrance (9). The name MEN1
syndrome has replaced the original name, Wermer’s
syndrome. The MEN1 clinical phenotype was fully char-
acterized in the 1960s. In 1988, the MEN1 locus was mapped
to chromosome 11q13 using recombinant DNA probes in
two brothers with MEN1 syndrome (10). Linkage analysis in
MEN1 families confirmed the 11q13 locus. In 1997, the
MEN1 gene was identified by positional cloning, and
mutations causing MEN1 syndrome were confirmed (11,12).
CLINICAL FEATURES
MEN1 is characterized by a combination of tumors of the
anterior pituitary, parathyroid, gastrointestinal tract, and
pancreas. Some patients may also develop adrenocortical
tumors, carcinoid tumors, facial angiofibromas, collageno-
mas, and lipomas. Tumors of the parathyroid are the first
manifestation of MEN1 in more than 85% of patients. In the
remaining patients, the first manifestation may be an
insulinoma or prolactinoma. Gastrointestinal and pancreatic
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tumors are gastrinomas, insulinomas, pancreatic polypepti-
domas (PPomas), glucagonomas, and vaso-active intestinal
polypeptidomas (VIPomas).
The most frequent MEN1-associated endocrinopathy,
which occurs in 90% of individuals with MEN1 between
the ages of 20 and 25 years, is primary hyperparathyroid-
ism, and it manifests as hypercalcemia in 100% of affected
individuals by 50 years of age. It is a multi-glandular
disorder with enlargement of all parathyroid glands
asynchronously and asymmetrically (7). Thus, increased
serum calcium and parathyroid hormone levels, renal
calculi, and bone demineralization should be actively
searched for in suspected cases (13).
MEN1 patients usually have a family history of MEN1,
and MEN1 gene mutations can be identified in 70% to 95%
of cases (1). Several endocrine tumors in MEN1 are benign
and cause symptoms by hypersecretion of hormones or
local mass effects, while other MEN1-related tumors are
associated with a very high risk of malignancy as
gastrinomas and carcinoid tumors (1,4). About one-third
of patients affected with MEN1 will die early from an
MEN1-related cancer or metabolic disturbance (14–16).
Consequently, the average age of death in individuals with
MEN1 is significantly lower than that in the general
population. MEN1 syndrome occurs in approximately 1 in
30,000 individuals, with an equal sex distribution, and there
is no ethnic or racial predilection (14).
MOLECULAR AND GENETIC CHARACTERISTICS
MEN1 gene is a tumor suppressor gene localized on
chromosome 11q13. It contains 10 exons spanning about 10
kb and encodes menin, a 610-amino-acid protein. The first
exon and part of exon 10 are not translated. A major
transcript of 2.8 kb has been described in a wide variety of
human tissues such as the pancreas, thymus, adrenals,
thyroid, testis, leukocytes, heart, brain, lung, muscle, small
intestine, liver, and kidney (7).
Menin is a nuclear protein with a wide variety of molecular
interactions with proteins that are involved in transcriptional
regulation, genome stability, proliferation, and cell division
(17,18). It acts as a scaffold to regulate gene transcription by
coordinating chromatin remodeling and is an essential
component of the histone methyltransferase complex. The
proposed mechanism by which MEN1 mutations lead to
tumor formation is by disruption of the interactions between
menin and other proteins, thus altering critical events in cell
cycle regulation and proliferation (19,20).
Over 1,300 mutations have been reported, scattered in
and around the open reading frame without significant
clustering, predominantly in coding exons but also within
intronic sequences (21,22). The majority of the mutations
result in premature stop codon generation (.70%). Most of
the mutations are unique, and only a few are reported in
more than 2% of cases. About 45% of the mutations are
deletions, 25% are nonsense mutations, 15% are insertions,
10% are missense mutations, and less than 5% are splice-site
mutations (22). MEN1-founding mutations have been
described in Europe (France, Finland, and Sweden), North
America (United States, Canada), South America (Brazil),
and Oceania (Australia) (7,23–26).
TheMEN1mutations inactivate the gene and are consistent
with those expected for a tumor suppressor (22). More
than 90% of tumors from MEN1 patients have loss of
heterozygosity (LOH), and this has been taken as evidence
that the disease follows Knudson’s two-hit model of
tumorigenesis (27). The first hit is a heterozygous MEN1
germline mutation inherited from one parent (familial
cases) or developed in an early embryonic stage (sporadic
cases) and is present in all cells at birth. The second hit is
an MEN1 somatic mutation that occurs in the predisposed
endocrine cell, giving the survival advantage needed for
tumor development (28).
MEN1 syndrome has high penetrance. Half of patients
develop signs and symptoms by 20 years of age, and more
than 95% will have symptoms by 40 years of age (29). There
is significant variability in the age of onset, severity of
disease, and tumor types. Despite numerous studies, no
genotype-phenotype relation has been established, and no
correlations have been detected between MEN1 mutations
and clinical manifestations (1).
Ten percent of patients with the MEN1 syndrome may
not harbor mutations in the coding region of the MEN1
gene, and whether these individuals have whole gene
deletions or mutations in the promoter or untranslated
region remains to be investigated. One study showed that
33% of patients who do not have mutations within the
coding region have large deletions involving complete
exons not easily detected by DNA sequence analysis (30).
MEN1 families without inactivation of the MEN1 gene
may also present mutations in other genes. Pellegata et al.
first reported a CDKN1B-inactivating germline mutation in
a family with an MEN1-like phenotype (MEN4 syndrome)
involving cases with acromegaly, primary hyperparathyr-
oidism, renal angiomyolipoma, and testicular cancer (31). A
second CDKN1B germline mutation was described in an
apparently ‘‘sporadic’’ MEN1 patient with adrenocortico-
tropic hormone secreting pituitary adenoma (Cushing’s
disease) (32). Recently, other CDKN1B mutations were
identified in a very large cohort of patients with MEN1-
related states in whom no detectable MEN1 mutation was
found (33). Of note, none of these CDKN1B-mutation-
positive patients had developed pituitary adenomas. These
data suggested that the tumoral susceptibility caused by
CDKN1B inactivation needs to be further evaluated and that
the association of CDKN1B mutations with pituitary disease
may be less common than initially thought. Agarwal et al.
demonstrated that patients with MEN1 states may rarely
harbor germline mutations in other genes encoding cyclin-
dependent kinase inhibitors (CDKIs), such as CDKN2B/
p15INK4b, CDKN2C/p18-INK4C, and CDKN1A/p21
CIP1 (33). A mutation in the CDKN1A/p21CIP1 gene was
associated with pituitary tumors (macroprolactinomas) in
two relatives. In conclusion, our knowledge about the role
of the CDKI genes in the susceptibility to familial pituitary
adenomas is still limited owing to the small number of
patients with mutations reported so far (31–33).
PITUITARY TUMORS IN MEN1
Prevalence
The prevalence of pituitary tumors may vary widely,
from 10% to 76% of MEN1 cases, depending on the studied
series (26,29,34). Of note, the prevalence of pituitary tumors
in MEN1 in several large series consisting of small families
affected by MEN1 (less than five affected cases per family)
differs markedly from the few very large MEN1 genealogies
(.20 affected cases per family) so far reported (26). MEN1
Pituitary tumors and MEN1 syndrome
Syro LV et al.
CLINICS 2012;67(S1):43-48
44
cases in the latter families are usually caused by a founding
MEN1 gene, and some of them may present very high
frequencies of pituitary tumors, such as those reported in
Newfoundland and Brazil (26,35).
General characteristics
Amongst 1,500 pituitary adenomas surgically resected
at the Mayo Clinic, 41 (2.7%) occurred in the setting of
MEN1 (36). In patients with MEN1, the frequency of func-
tional adenomas, mainly prolactin and growth hormone-
producing tumors, was higher than that of sporadic
adenomas. There was, however, no difference in age,
gender, tumor size, or invasiveness.
In 1980, Farid et al. described a syndrome of prolacti-
noma, carcinoid, and hyperparathyroidism in four large
families from Newfoundland (37). This variant is now
referred to as MEN1-Burin, for the region the affected
patients were from (the Burin Peninsula). These patients
presented frequently with prolactinoma and carcinoid. A
nonsense mutation of the MEN1 gene, which was respon-
sible for the disease in these patients, was found later (35).
Burgess et al. described another prolactinoma variant,
MEN1-Tasman (34). In this case, prolactinomas occurred
in 76% and nonfunctional adenomas in 24% of patients.
Recently, a foundingMEN1 gene mutation was detected in a
large MEN1 Brazilian family, and a high frequency of
pituitary tumors was verified (26).
In a France–Belgium multicenter study, 324 MEN1
patients were analyzed; 136 MEN1 patients with a pituitary
adenoma were compared to 110 control patients with
sporadic pituitary adenomas. No significant differences
were detected in the types of adenomas, but the mean age of
patients with pituitary disease as the initial manifestation
of MEN1 was significantly lower (33.9¡14 years) than that
of patients showing a primary endocrine, intestinal, or
pancreatic tumor (41.6¡14 years). The study also showed
that the delay between initial and subsequent MEN1
endocrine lesions was significantly longer when pituitary
disease was the initial MEN1 manifestation (9.0¡8.1 years)
than when the initial manifestation was intestinal and
pancreatic tumors (4.1¡4.0 years) or hyperparathyroidism
(5.2¡5.1 years) (38).
Clinical characteristics
In the France-Belgium multicenter study, the frequency
of pituitary macroadenomas was significantly higher in
MEN1 patients than in non-MEN1 subjects (85% vs. 42%)
(38). Clinical manifestations related to the size of pituitary
adenoma were significantly more frequent in MEN1
patients than in non-MEN1 subjects (29% vs. 14%).
Pituitary adenomas with initial manifestation occurred
in 17% of patients and were more frequent in women than
in men. Normalization of pituitary hypersecretion was
much less frequent in MEN1 patients than in non-MEN1
subjects (42% vs. 90%). In a recent publication, the authors
found a gender-related difference showing that the
prevalence and probability of developing pituitary tumors
were significantly greater in females than in males (39). A
family history of MEN1 was more frequently found in
men than in women at the time of diagnosis. Pituitary
tumors occurred as the first clinical manifestation of
MEN1 syndrome in 25% of sporadic and in 10% of familial
cases (7).
Morphologic characteristics
In a study by Trouillas et al. of 211 MEN1 patients, 77
surgically removed pituitary adenomas were described
and compared with 2,509 unselected non-MEN1 sporadic
pituitary tumors (40). These authors also compared a control
subgroup of 296 cases from the latter group in which non-
MEN1 cases were matched with MEN1 cases at the time of
surgery and the immunoprofile of the tumor. The results
showed that patients with MEN1 were younger and had
larger tumors. The tumors of patients with MEN1 syndrome
were more often invasive. The types of lesions were
significantly different in MEN1 and non-MEN1 patients
owing to the higher frequency of multiple adenomas (4% vs.
0.1%) and hyperplasia (4% vs. 0%) in the MEN1 patients. The
frequency of functional pituitary adenomas was identical in
the two groups (72% MEN1 vs. 64% non-MEN1), but the
proportion of plurihormonal adenomas was significantly
higher in the MEN1 group. Regarding immunoexpression,
they did not find predominance of any functional subtype. It
is important to note that in patients with pituitary hyperpla-
sia, tumors producing a releasing hormone such as growth-
hormone-releasing hormone must be investigated. Adenoma
multiplicity may underlie surgical failure in cases in which
one adenoma is removed and the other is left behind (41).
Treatment
Treatment of pituitary tumors depends on clinical
presentation, and its aims are tumor volume diminution,
normalization of hormone hypersecretion, and preservation
of normal pituitary function. Surgery, medication (dopa-
mine agonists, somatostatin analogs, growth hormone
receptor antagonists) and radiotherapy are used. The choice
of treatment depends on hormone hyperproduction (pro-
lactin or growth hormone), the size and invasion of the
tumor, presence of visual impairment, the presence of
associated comorbidities, the response or lack of response to
medical treatment, contraindications, and the patient’s
preference. The treatment is the same for sporadic and
MEN1-associated pituitary tumors. There are insufficient
data in the literature to propose a different approach at
present. A closed surveillance is recommended.
Risk of malignant progression
Although it was reported that pituitary tumors were
larger and more often invasive in patients with MEN1
syndrome than in patients with sporadic tumors, malignant
tumors were not more frequent. However, three cases of
pituitary carcinomas were recently reported in patients with
MEN1. The first one was a female with sporadic MEN1 and
gonadotroph pituitary carcinoma (42). The second was a
male with prolactin-producing carcinoma with familial
MEN1 (43), and the third was a male with a thyrotropin-
producing carcinoma in sporadic MEN1 (44). Owing to the
low frequency of pituitary carcinomas, which represent
about 0.1–0.2% of all cases of pituitary tumors, it is
intriguing that three MEN1-associated cases have been
reported.
FUTURE PERSPECTIVES
Despite significant efforts in the past decade, little is
known about genetic alterations in patients with sporadic
pituitary tumors. Recent interest in genetics and molecular
alterations in patients with pituitary tumors has led to a
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better understanding of the different syndromes involved in
the development of MEN1, Carney complex, McCune–
Albright syndrome and familial acromegaly (20,28,45,46). A
number of genetic factors, hormones, growth factors,
adhesion molecules and cell cycle regulators may be
involved in these syndromes. Their study could help to
elucidate the process of pituitary tumor initiation and
progression.
Information related to human genes is accumulating at an
ever-increasing pace, and the growing inventory of genetic
variations is facilitating our understanding of the same
disease among individuals and populations. MEN1-found-
ing mutations have been described in different places
around the world. The prevalence, severity, and resistance
to treatment could differ among ethnic groups as a
consequence of inherited and noninherited causes. It will
be important in the future to analyze whether or not these
groups possess ancestral similarities that could explain
differences in clinical characteristics (47). Comparison of the
prevalence of the two most important components of
human genetic variation, single-nucleotide polymorphisms
and copy-number variants, among these populations will
provide us with better insight into MEN1. The use of
ancestry in mapping genes that contribute to the develop-
ment and progression of pituitary tumors in MEN1 may
help us to understand the causes of disease and health
disparities between these patients all around the world.
Genomic data present a new array of opportunities and
challenges, and data collection should be extended to as
many diverse populations as possible.
Future study of MEN1 and pituitary tumors includes the
application of ‘‘omic’’ technologies (genomics, transcrip-
tomics, proteomics, and metabolomics). Contrary to tradi-
tional molecular biology methods that were used to study
the role of a single gene and single protein, ‘‘omic’’ data
along with a systems biology approach will help us to apply
a multiple-factor model of disease and to clarify the network
of interactions and regulatory events that contribute to
disease (48,49).
Finally, the use of exome sequencing will offer new
opportunities for research on Mendelian disorders. Exome
sequencing has now been applied in multiple situations
individually where the causal variants for a number of
Mendelian disorders have been successfully identified. In
addition, exome sequencing has been shown to be more
rewarding in the study of disorders with genetic and
phenotypic heterogeneity such as MEN1 (50–52). High-
throughput sequencing may also be helpful in uncovering
new genetic variants among MEN1 patients with no
mutations apparent from conventional PCR and exon
sequencing.
CONCLUSION
MEN1 is a complex syndrome in which a large number of
endocrine and non-endocrine neoplasias may occur. The
occurrence of anterior pituitary tumors in MEN1 syndrome
may range between 10% and 60%. Pituitary involvement
includes the initial manifestation of MEN1 syndrome in 10%
to 25% of individuals (38,53). Pituitary adenomas are
significantly more frequent in women than in men.
Approximately 65% to 85% of pituitary tumors in MEN1
syndrome are macroadenomas. Plurihormonal adenomas
occur more frequently than monohormonal adenomas in
MEN1. Most cases are prolactinomas, somatotropinomas,
and non-secreting tumors, although three cases of pituitary
carcinoma were reported. In some families, including four
families from Newfoundland reported as the so-called
MEN1-Burin variant, prolactinoma is unusually common.
Specific cases presenting isolated familial prolactinomas or
somatotropinomas need to be differentiated from cases with
familial acromegaly/gigantism owing to germline muta-
tions in the AIP gene (54).
When pituitary adenomas present as the initial manifesta-
tion of MEN1, they occur at an earlier age than when the
initial manifestation is an endocrine, intestinal, or pancreatic
tumor. Pituitary tumors in patients with MEN1 syndrome
tend to be larger, more frequently invasive and more
symptomatic, and they occur in younger patients. The
normalization of pituitary hypersecretion occurs much less
frequently in MEN1 functional adenomas than in sporadic
adenomas. They are more frequently multi-hormonal and
mixed tumors. Pituitary hyperplasia and multiple tumors
are more frequently found in MEN1 pituitary tumors than
in sporadic cases, although no significant differences were
noticed.
In summary, pituitary tumors associated with MEN1 may
differ markedly from sporadic tumors, and these differences
are usually very helpful in performing the differential
diagnosis between these entities. Briefly, pituitary tumors in
MEN1 (a) are usually diagnosed at earlier ages than
sporadic pituitary adenomas and occur more frequently in
females; (b) have a higher degree of aggressiveness and
invasiveness; (c) have a higher prevalence of macroadeno-
mas; (d) more frequently present as multi-hormonal and
mixed tumors; (e) are more often resistant to medical
therapy; and (f) have higher tumor recurrence rates.
Furthermore, pituitary hyperplasia and multiple pituitary
tumors are more frequently found in MEN1 than in
sporadic tumors, although no significant differences were
noticed.
Finally, it is important to obtain genetic MEN1 mutation
screening in MEN1 family members at risk to present with
disease. This has a strong clinical impact that can lead to
decreased morbidity rates and possibly decreased mortality
rates, and this screening should be routinely performed
(55,56).
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